Elpiscience Signs $117 Million Deal for TRIGR Bispecific

Elpiscience Biopharma of Shanghai acquired China rights to an anti-VEGFxDLL4 bispecific antibody being developed by TRIGR Therapeutics of Irvine, CA. TRIGR is already conducting a US Phase I trial of TR009 as a fourth-line therapy in patients with colorectal or gastric cancer. Elpiscience will make a $7 million upfront payment and be responsible for up to $110 million in milestones, plus royalties. An immunotherapy company, Elpiscience is developing 12 products including a bispecific anti-PD-1 in China trials. One year ago, the company raised $100 million in Series B funding. More details.... Share this with colleagues: // //